Fox Chase Cancer Center
NexusPharma has entered into general agreements and has licensed intellectual property from Fox Chase that are providing the basis for its protein interaction technology and enabling the discovery and development of novel therapies based on small-molecule PPIIs. In addition, the company has entered into a collaborative research agreement with Fox Chase enabling access to its renowned scientific expertise and first-rate research facilities.

Other Collaborations
The Company is supported by a highly regarded international network of scientific collaborators, development experts, and other expert advisors, enabling a “virtual” development framework with:
- specific biological expertise at universities and institutions such as the University of North Carolina at Chapel Hill, the University of California at Los Angeles, the University of Pennsylvania, as well as the University of Munich, Germany.
- collaborations on animal models and further drug development through the National Cancer Institute.
- animal pharmacokinetic and pharmacodynamic studies, and custom medicinal chemistry, through contract research organizations (CROs).
Home | Contacts | Directions